Pharmacokinetic and pharmacodynamic evaluation of ceftaroline fosamil.

about

Pharmacokinetics of ceftaroline in normal body weight and obese (classes I, II, and III) healthy adult subjects A critical review on the clinical pharmacokinetics, pharmacodynamics, and clinical trials of ceftaroline.

P2860

Q35746176-E91FE6A5-44EF-47AC-8A3E-417551D670B6 Q38458802-2E1D8AA6-8888-4BA5-AAAE-9DF7A013ACA6

P2860

Pharmacokinetic and pharmacodynamic evaluation of ceftaroline fosamil.

Item

http://www.wikidata.org/entity/Q38262950

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Pharmacokinetic and pharmacodynamic evaluation of ceftaroline fosamil.

@en

type

Item

label

Pharmacokinetic and pharmacodynamic evaluation of ceftaroline fosamil.

@en

prefLabel

Pharmacokinetic and pharmacodynamic evaluation of ceftaroline fosamil.

@en

P1476

Pharmacokinetic and pharmacodynamic evaluation of ceftaroline fosamil.

@en

P2093

Andrew Merker

http://www.w3.org/2001/XMLSchema#string

Keith A Rodvold

http://www.w3.org/2001/XMLSchema#string

Larry H Danziger

http://www.w3.org/2001/XMLSchema#string

Robert C Glowacki

http://www.w3.org/2001/XMLSchema#string

P2860

Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections

Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States.

Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains.

Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target.

Ceftaroline versus ceftriaxone in a highly penicillin-resistant pneumococcal pneumonia rabbit model using simulated human dosing.

Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolates

Efficacy of ceftaroline fosamil in a staphylococcal murine pneumonia model.

Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.

Single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjects

In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.

P304

1741-1750

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17425255.2014.972932

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-10-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25347329

http://www.w3.org/2001/XMLSchema#string

Pharmacokinetic and pharmacodynamic evaluation of ceftaroline fosamil.

about

P2860

P2860

Pharmacokinetic and pharmacodynamic evaluation of ceftaroline fosamil.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698